Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

K.‐C., Julian; Hikmat, Ban Y.; Wycoff, Keith L.; Vine, Nicholas D.; Chargelegue, Daniel; Yu, Lloyd; Hein, Mich B.; Lehner, Thomas

doi:10.1038/nm0598-601

Cited by 451 publications

(259 citation statements)

References 18 publications

Supporting

Mentioning

248

Contrasting

Unclassified

Order By: Relevance

“…Passive immunization with antibodies from several different species has been used as immunotherapy against dental caries (25,26) and periodontitis (27)(28)(29)(30)(31)(32). Previous studies have shown that antibodies are actively transported to the egg yolk of immunized hens (33).…”

Section: Discussionmentioning

confidence: 99%

Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients

et al. 2007

View full text Add to dashboard Cite

Porphyromonas gingivalis gingipains issuspected to be one of the most important causative agents of periodontitis. We postulated that the inhibition of gingipains may reduce the pathogenic nature of P. gingivalis. Anti-P. gingivalis egg yolk antibody (IgY-GP) was isolated from the yolks of hens immunized with purified gingipains. We applied IgY-GP gel subgingivally in periodontitis patients who harbored P. gingivalis in their subgingival flora. Five pairs of contralateral anterior single-rooted teeth were selected. One tooth in each contralateral pair was randomly treated with IgY-GP and subgingival scaling and root planing, whereas the other tooth was treated with SRP alone. The number of P. gingivalis bacteria was assessed by real-time PCR. Bacterial levels were expressed as the percentage of total bacteria. The IgY-GP group had a significant reduction in probing depth. BOP significantly decreased in the IgY-GP group compared to the control group at week 4. The levels of P. gingivalis significantly increased in the control group at week 4, whereas the reduction in the levels of P. gingivalis was sustained in the IgY-GP group. Within the limitations of the present study, IgY-GP was shown to be an effective immunotherapeutic agent in the treatment of periodontitis. (J. Oral Sci. 49,[201][202][203][204][205][206] 2007)

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Only one of these has been tested in humans: a chimeric secretory IgG-IgA antibody against a surface antigen of Streptococcus mutans, the primary causal agent of tooth decay. This tobacco-produced antibody was applied topically to teeth and found to be as effective as an IgG produced in a murine hybridoma at preventing recolonization by S. mutans 8 . The second antibody, a humanized anti-herpes-simplex virus (HSV) antibody made in soybean, was effective in the prevention of vaginal HSV-2 transmission in a mouse model 3 .…”

Section: Antibody Production In Plantsmentioning

confidence: 99%

“…For mucosal applications, this is not likely to present problems for most people because plant glycoproteins are ubiquitous in the human diet. There has been no evidence of allergic reaction or of a human anti-mouse antibody (HAMA) response in 60 patients receiving topical oral application of a secretory IgA specific to S. mutans 8 .…”

Section: Antibody Production In Plantsmentioning

confidence: 99%

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Daniell

Streatfield²,

Wycoff

2001

Trends in Plant Science

Self Cite

661

412

View full text Add to dashboard Cite

The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than those derived from animals. Here, we discuss recent developments in this field and possible environmental concerns.

show abstract

“…The secretory version of this antibody accumulated at high levels in the plant, retained specificity against Streptococcus mutans, and conferred protection against dental caries [35]. In fact, a milestone for plant molecular farming was the first EU approval for the commercialization of a plant-made recombinant product, which was awarded to California based company Planet-Biotech for the production of sIgG/A as a medical device for human health.…”

Section: Deleted: Itsmentioning

confidence: 99%

“…Deleted: [20,34] Deleted: [35] Deleted: SIgA In their natural biofactories, the lymphocytes, antibodies are synthesized through the cell endomembrane system. Antibody synthesis requires coordinated expression, folding and assembly of H and L chains.…”

Section: Deleted: Alsomentioning

confidence: 99%

Manufacturing antibodies in the plant cell

Orzáez

Granell

Blázquez

2009

Biotechnology Journal

View full text Add to dashboard Cite

International audiencePlants have long been considered advantageous platforms for large-scale production of antibodies due to their low cost, scalability, and the low chances of pathogen contamination. Much effort has therefore been devoted to efficiently produce mAbs (from nanobodies to secretory antibodies) in plant cells. Several technical difficulties have been encountered and are being coped with. Improvements in production levels have been achieved by manipulation of gene expression and, more efficiently, of cell targeting and protein folding and assembly. Differences in mAb glycosylation patterns between animal and plant cells are being successfully addressed by the elimination and introduction of the appropriate enzyme activities in plant cells. Another relevant battlefield is the dichotomy between production capacity and speed. Classically, stably transformed plant lines have been proposed for large scale mAb production, whereas the use of transient expression systems has always provided production speed at the cost of scalability. However, recent advances in transient expression techniques have brought impressive yield improvements, turning speed and scalability highly compatible assets. In the era of personalized medicines, the combination of yield and speed, and the advances in glyco-engineering have made the plant cell a serious contender in the field of recombinant antibody production

show abstract

Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans

Cited by 451 publications

References 18 publications

Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients

Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Manufacturing antibodies in the plant cell

Contact Info

Product

Resources

About